Pharmacological induction of fetal hemoglobin (HbF) expression is an effective treatment strategy for sickle cell disease (SCD) and β-thalassemia. Pomalidomide is a potent structural analog of thalidomide and member of a new class of IMiDs® immunomodulatory drugs . Recent reports demonstrated that pomalidomide reduced or eliminated transfusion requirements in certain hematological malignancies and induced HbF ex vivo in CD34+ progenitor cells from healthy and SCD donors. We investigated the effects of pomalidomide on erythropoiesis and hemoglobin synthesis in a transgenic mouse model of SCD. We found that eight weeks of treatment with pomalidomide induced modest increases of HbF with similar efficacy as hydroxyurea. However, in stark contrast to hydroxyurea's myelosuppressive effects, pomalidomide augmented erythropoiesis and preserved bone marrow function. Surprisingly, combinatory therapy with both drugs failed to mitigate hydroxyurea's myelotoxic effects and caused loss of HbF induction. These findings support further evaluation of pomalidomide as a novel therapy for SCD.
Introduction
Substantial experimental and clinical evidence support the development of targeted therapies for the induction of fetal hemoglobin in patients with SCD. [1] [2] [3] [4] [5] [6] Hydroxyurea, a ribonucleotide reductase inhibitor, is the most thoroughly investigated and only FDA approved treatment for adult patients with SCD that augments HbF expression and reduces clinical complications. 7, 8 Despite this progress, there is an unabated need for targeted HbF inducing therapies because many patients fail to respond to hydroxyurea. Pomalidomide and lenalidomide are proprietary thalidomide analogs, which belong to a novel class of IMiDs® immunodulatory drugs. Both compounds recently emerged from clinical trials as highly promising treatments for various hematological cancers and chronic inflammatory conditions. 9-11 Surprisingly, both IMiDs compounds were also found to restore erythropoiesis and to reduce or eliminate blood transfusion dependency in patients suffering from multiple myeloma and myelodysplastic syndromes. [12] [13] [14] [15] Furthermore, a recent ex vivo study demonstrated that pomalidomide and lenalidomide not only stimulated the proliferation of CD34+ progenitor cells and total hemoglobin production, but also upregulated HbF synthesis by a transcriptional mechanism. 16 In this system, pomalidomide enhanced HbF synthesis more potently than lenalidomide and hydroxyurea and acted synergistically in combination with hydroxyurea. These results prompted the current study to evaluate pomalidomide's hematological properties in a relevant in vivo model of SCD.
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Methods

Mice
Knockout-transgenic sickle cell mice were bred at Georgia Health Sciences University according to institutional guidelines. 17 Treatment groups consisted of vehicle (saline; n=8); pomalidomide (10 mg/kg; n=9); hydroxyurea (100 mg/kg; n=7); pomalidomide (10 mg/kg) + high-dose hydroxyurea (100 mg/kg; C/HD; n=8); pomalidomide (10 mg/kg) + low-dose hydroxyurea (10 mg/kg; C/LD; n=8). Pomalidomide (Celgene; Summit NJ) and hydroxyurea (Sigma) were mixed in saline and injected i.p. daily (Mon-Fri) for eight weeks. C57BL/6 mice were used for specific control experiments. Details of the mouse model, drug preparation and dose selection are included in Supplemental data. The study was approved by GHSU's Animal Care and Use
Committee.
Pharmacokinetic analysis
See supplemental data for detailed information.
Complete blood count and RBC indices
Blood was collected by intracardiac puncture from ketamine/xylazine anesthetized mice in vacutainer EDTA tubes (Becton-Dickinson) and CBC analyzed with the CBC-Diff™ Veterinary Hematology System (Heska Corporation). Reticulocyte counts were determined by supravital staining with methylene blue.
Fetal hemoglobin analysis
Hemoglobin analysis from mouse hemolysates was done by analytic HPLC using a weak cationexchange column SynChropak CM-300 (Eprogen INC) on the Waters Empower 32 HPLC system (Millipore Corporation).
F-cells
F cells were analyzed by flow cytometry using the Caltag fetal hemoglobin test kit (Caltag Laboratories) according to the manufacturer's instructions. Flow cytometry was performed using the BD FACSCalibur system (BD Biosciences). HbF/F-cell (pg/cell) was calculated using mean cell hemoglobin (MCH) x %HbF / %F-cell.
Histology
Formalin-fixed bone marrow sections (4 microns) of the proximal femur were stained with H&E (Richard-Allan Scientific) and analyzed by two blinded investigators for the M:E ratio.
Statistics
Data are presented as mean ± SEM. Groups were analyzed by One-Way Analysis of Variance (ANOVA) followed by Student-Newman-Kuels. A p value < 0.05 was considered significant.
Results and discussion
Pomalidomide was well tolerated by sickle cell mice without signs of toxicity and with similar absorption and elimination properties compared to BL/6 control mice (supplemental Figure 2) .
Pomalidomide increased the level of HbF expression from 6.24% at baseline to 9.51% after eight weeks of treatment, which was comparable to hydroxyurea ( Figure 1A ) and similar to the magnitude of HbF induction observed in adult sickle cell patients treated with hydroxyurea in the MSH trial. 7, 8 It is important to note that the human beta globin cluster transgene in our model only encodes for the Aγ globin gene sequence. Considering that pomalidomide is known to transcriptionally activate both Aγ and Gγ globin genes, this transgene design may have resulted in underreporting of pomalidomide's in vivo HbF activity. 16, 17 The increase in HbF expression in the pomalidomide and hydroxyurea groups was accompanied by a higher HbF content per F-cell without parallel increases in the F-cell percentage ( Figure 1A ). This lack of an F-cell response is most likely related to the high pretreatment F-cell values of ≥ 50% which is in agreement with the observed inverse relationship between the F-cell response to hydroxyurea and pretreatment Fcell values in a clinical trial of young patients with SCD. 18 Motivated by the synergistic HbFinducing activity of pomalidomide and hydroxyurea in ex vivo CD34+ progenitor cells, we conducted combinatory treatments and surprisingly observed a virtual loss of HbF induction above control levels ( Figure 1A ). We tested a combination of pomalidomide with a lower dose of hydroxyurea (10 mg/kg) to rule out compound toxicity as the cause of HbF inhibition.
Interestingly, this regimen recovered bone marrow function but continued to block HbF production. The reason for this loss of HbF activity in the combined treatment groups is unclear, but could be related to the greater complexity of regulatory signals in the in vivo microenvironment or differences between the β -globin gene clusters in the two systems.
For
Ineffective erythropoiesis is a contributory factor to anemia in SCD, albeit to a much lesser extent than in β-thalassemia syndromes. We found that pomalidomide, in addition to modulating HbF expression, expanded the erythron and improved the efficiency of erythropoiesis as evidenced by a trend toward higher reticulocyte counts (Figure 1B-C; Table 1 ). Because of the physical constraints of the mouse bone marrow compartment, the spleen in sickle mice functions as the major hematopoietic organ and becomes massively enlarged. Pomalidomide significantly raised the peripheral RBC count, caused further increases in spleen weight, and decreased the myeloid to erythroid (M:E) ratio in bone marrow and spleen. Plasma free hemoglobin levels in the pomalidomide group were not different from controls indicating that gains in the peripheral RBC counts were not secondary to a protective effect of HbF production on F cell survival. However, we noted that expansion of the erythroid lineage was associated with significantly reduced RBC mean corpuscular volumes (MCV) and only small increases in total hemoglobin levels. These findings suggest residual defects in hemoglobin production possibly secondary to iron restricted erythropoiesis or the mild β -thalassemic phenotype in this model. In contrast, hydroxyurea treatment was associated with sharply lower reticulocyte counts, a significant increase in the M:E ratio in both hematopoietic organs, and a reduction of spleen weights to less than one-half of control values. Bone marrow megakaryocyte counts appeared unaffected by pomalidomide, but were significantly reduced by hydroxyurea. Compared to hydroxyurea, pomalidomide had no statistically significant effect on the total WBC count, but caused a significant reduction in the monocyte fraction which could have additional beneficial treatment effects because of the proinflammatory role of sickle monocytes in SCD. For
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